Blockchain Registration Transaction Record

Kadimastem and iTolerance Announce Breakthrough Treatment for Type 1 Diabetes

Kadimastem Ltd. and iTolerance Inc. announce positive results of their leading diabetes treatment at the ADA conference. The treatment, a combination of an immune modulator microgel material and insulin-producing islet cells derived from human stem cells, demonstrates functional insulin release and disease reversal in a model of diabetes.

The announcement of the breakthrough treatment for type 1 diabetes is a significant development in the field of diabetes research and treatment. The innovative approach, recognized by the Diabetes Research Institute at the University of Miami, offers hope for the potential cure of insulin-dependent diabetes without the need for life-long immunosuppression. This has the potential to revolutionize diabetes treatment and improve the quality of life for millions of people worldwide who are living with the disease.